Home › Hemophilia › California
Hemophilia clinical trials in California
14 studies for Hemophilia are looking for participants at sites in California.
Cities in California
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
- Children's Hospital Los Angeles- Site Number : 8400005, Los Angeles
RecruitingPhase 4
Ages 12 and older · Men · Updated Sep 23, 2026 · NCT06145373A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
- UC Davis Cancer Center, Sacramento
RecruitingPhase 1/2
Ages 2 to 59 · Men · Updated Sep 11, 2026 · NCT05987449A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
- Center for Inherited Blood Disorders, Orange
- University of California San Francisco, San Francisco
- Kaiser Permanente, Vallejo
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Sep 11, 2026 · NCT07226206A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- Center for Inherited Blood Disorders, Orange
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 4, 2026 · NCT07416604Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
- Lucile Packard Children's Hospital, Palo Alto
RecruitingObservational studyHealthy volunteers welcome
Ages 0 to 20 · All sexes · Updated Aug 21, 2026 · NCT04278404ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Orthopaedic Institute for Children HTC, Los Angeles
- Childrens Hospital Los Angeles, Los Angeles
- UCSF Benioff Children's Hospital Oakland, Oakland
- and 5 more
RecruitingObservational study
All ages · All sexes · Updated Aug 17, 2026 · NCT04398628A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
- The Luskin Orthopaedic Institute for Children- Site Number : 8400013, Los Angeles
- The Center for Inherited Blood Disorders- Site Number : 8400009, Orange
RecruitingPhase 3
Ages 1 to 11 · Men · Updated Aug 17, 2026 · NCT07285460A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
- Children's Hospital Los Angeles, Los Angeles
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 60 · All sexes · Updated Jul 2, 2026 · NCT06349473Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
- Stanford University, Palo Alto
- Rady Children's Hospital, San Diego
RecruitingObservational study
Ages 6 to 19 · All sexes · Updated Jul 2, 2026 · NCT05022459A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
- Orthopaedic Institute for Children/Orthopaedic Hemophilia Treatment Center, Los Angeles
RecruitingPhase 1
Ages 12 to 74 · Men · Updated Jun 3, 2026 · NCT06703606Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- The Regents of the University of California||UC Davis Health, Rancho Cordova
- UC Davis Health, Sacramento
- UC Davis Ambulatory Care Clinic, Sacramento
- and 3 more
RecruitingPhase 3
Ages 18 and older · Men · Updated May 27, 2026 · NCT05568719Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
- The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders (CIBD), Orange
- Stanford University: Stanford Children's Health, Redwood City
RecruitingPhase 1
Ages 0 to 90 · All sexes · Updated Apr 3, 2026 · NCT05500807SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
- Orthopaedic Institute for Children, Los Angeles
- University of California at Davis UC Davis Hemostasis and Thrombosis Center, Sacramento
RecruitingPhase 4
Ages 12 to 100 · All sexes · Updated Jan 12, 2026 · NCT04647227Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
- Orthopedic Institute for Children- Site Number : 8400009, Los Angeles
RecruitingPhase 4
Ages 12 and older · All sexes · Updated Nov 18, 2025 · NCT06941870From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.